Nonalcoholic Steatohepatitis Market Landscape and Emerging Opportunities
Nonalcoholic steatohepatitis (NASH), a progressive form of metabolic liver disease, is attracting increasing attention because of its association with liver inflammation, hepatocyte injury, fibrosis, cirrhosis, and potentially end-stage liver disease. DelveInsight estimates that the NASH market across the seven major markets (7MM)—the United States, EU4, the United Kingdom, and Japan—was approximately USD 2,114 million in 2023 and is projected to increase during 2024–2034.
The growing burden of obesity, type 2 diabetes, metabolic syndrome, and other metabolic risk factors is contributing to increasing disease prevalence and creating opportunities for pharmaceutical companies, diagnostic developers, and healthcare stakeholders. In 2023, approximately 42 million NASH prevalence cases were estimated across the 7MM, while around 15 million were diagnosed.
The broader non-alcoholic steatohepatitis market is also evolving as the industry moves toward therapies capable of addressing steatohepatitis and fibrosis. At the same time, better disease characterization and diagnostic innovation are becoming increasingly important for identifying patients and monitoring progression.
Identify emerging NASH therapies, epidemiological trends, unmet needs, and competitive opportunities through detailed market intelligence. Request NASH Market Insights
NASH Market Size and Regional Dynamics
The United States represents a substantial portion of the overall NASH opportunity. According to DelveInsight, the US NASH market was approximately USD 1,519 million in 2023, making it the largest market among the 7MM. Japan represented another important market, with a NASH market size of nearly USD 260 million in 2023.
Within Europe, Germany had the largest NASH market in 2023 at approximately USD 89 million, while Spain accounted for around USD 50 million. These variations reflect differences in diagnosed patient populations, healthcare systems, treatment practices, and market access.
Regional research is also becoming increasingly relevant to biomarker development. Searches and commercial assessments may address opportunities such as the india non alcoholic steatohepatitis biomarkers market, spain non alcoholic steatohepatitis biomarkers market, and uk non alcoholic steatohepatitis biomarkers market as diagnostic technologies become more important in disease management.
Therapeutic Innovation Reshaping the NASH Market
The therapeutic landscape has entered an important period of development following the introduction of REZDIFFRA (resmetirom). In March 2024, Madrigal Pharmaceuticals’ resmetirom received accelerated FDA approval for adults with noncirrhotic NASH with moderate to advanced liver fibrosis consistent with F2–F3 stages. DelveInsight identifies REZDIFFRA as the first FDA-sanctioned therapy for this patient population.
The emergence of an approved therapy provides a foundation for continued innovation while encouraging research into additional mechanisms and treatment strategies. The pipeline includes therapies targeting metabolic pathways, fibrosis, inflammation, lipid metabolism, and other disease mechanisms.
Pegozafermin, an FGF21-targeting therapy developed by 89bio, entered a Phase III ENLIGHTEN-Cirrhosis trial in May 2024. Efruxifermin, an Fc-FGF21 fusion protein developed by Akero Therapeutics, entered the Phase III SYNCHRONY Outcomes study for patients with compensated cirrhosis caused by NASH.
Other emerging approaches include PPAR modulation, GLP-1 receptor agonism, FASN inhibition, FXR agonism, and additional metabolic or antifibrotic strategies. This diverse pipeline could expand treatment options and influence future market dynamics.
Explore detailed NASH market forecasts, epidemiology, therapies, and emerging opportunities with DelveInsight. View the NASH Market Report
NASH Diagnostics and Biomarker Development
Diagnosis remains an important component of the NASH landscape because disease progression can occur with limited symptoms. DelveInsight’s analysis covers diagnostic methods, epidemiology, diagnosed patient populations, and disease severity across major markets.
The nonalcoholic steatohepatitis therapeutics diagnostics market therefore encompasses both treatment innovation and improvements in disease identification. The report evaluates current treatment practices, emerging therapies, market trends, unmet needs, and diagnostic considerations across the United States, EU4, the UK, and Japan.
Similarly, the term nonalcoholic steatohepatitis therapeutics diagnostic market reflects the increasing intersection between therapeutic development and diagnostic technologies. Biomarkers can support disease assessment, patient identification, risk stratification, and monitoring, potentially reducing reliance on more invasive approaches in appropriate clinical settings.
The expansion of biomarker research could create opportunities across established and emerging healthcare markets. This includes interest in country-specific segments such as the india non alcoholic steatohepatitis biomarkers market, spain non alcoholic steatohepatitis biomarkers market, and uk non alcoholic steatohepatitis biomarkers market.
Epidemiology Driving Market Expansion
Epidemiology is a major factor influencing the future of the NASH market. DelveInsight estimates that approximately 9.4 million diagnosed NASH cases were present in the United States in 2023, while EU4 and the UK collectively accounted for approximately 3.6 million diagnosed cases and Japan approximately 2.5 million.
The report also identifies differences according to disease severity. In the United States, F1-stage cases represented approximately 38% of diagnosed cases in 2023. Across the 7MM, diagnosed prevalent cases were higher among males, who represented approximately 56% of the diagnosed population.
These epidemiological patterns are important for pharmaceutical companies and diagnostic developers because they help define addressable patient populations, potential treatment demand, clinical trial opportunities, and healthcare resource requirements.
The relationship between NASH and the broader non alcoholic fatty liver disease market is also significant. NASH represents a more advanced disease state within the spectrum of metabolic fatty liver disease, making the progression from fatty liver disease to steatohepatitis and fibrosis an important consideration for healthcare planning.
Market Drivers and Unmet Needs
Several factors could influence NASH market development through the forecast period. Increasing awareness, rising metabolic risk factors, improvements in diagnosis, and the introduction of new therapies are among the major factors supporting market expansion. DelveInsight also highlights incremental healthcare spending and improved understanding of disease pathogenesis as factors that could support innovation.
At the same time, significant unmet needs remain. NASH is heterogeneous, and patients can experience different levels of fibrosis and disease progression. Identifying patients earlier and accurately assessing disease severity remain important clinical challenges.
The development of noninvasive biomarkers and diagnostic tools could therefore complement therapeutic innovation. As clinical research advances, companies may increasingly focus on integrated approaches combining patient identification, disease monitoring, and targeted therapeutic intervention.
Future Outlook for the NASH Therapeutics and Diagnostics Market
The future of the NASH landscape will likely be shaped by the interaction between approved therapies, late-stage pipeline candidates, diagnostic innovation, and evolving understanding of disease biology. DelveInsight’s report evaluates historical and forecasted market trends through 2034 and covers the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
The nash press release revenue 2024 search landscape also reflects the growing flow of corporate announcements, clinical-development updates, regulatory milestones, and investment activity surrounding the indication. Meanwhile, searches such as nash.io about us nash market vertical belong to a separate web-property context and should not be interpreted as evidence for the pharmaceutical NASH market covered by DelveInsight.
As market participants evaluate opportunities, combining epidemiological data with therapy uptake, pipeline analysis, competitive intelligence, and diagnostic trends can provide a more comprehensive view of the market. DelveInsight’s assessment includes marketed and emerging therapies, clinical trials, treatment practices, market drivers, barriers, and unmet needs.
Access comprehensive NASH market intelligence to evaluate forecasts, pipeline developments, epidemiology, and emerging opportunities. Access the Full NASH Market Analysis
Conclusion
The NASH market is entering a transformative phase supported by rising disease burden, therapeutic innovation, diagnostic advances, and increasing clinical understanding. DelveInsight estimates the 7MM NASH market at approximately USD 2,114 million in 2023, with continued growth projected through 2034. The approval of resmetirom and development of therapies such as pegozafermin and efruxifermin demonstrate the expanding therapeutic landscape. Meanwhile, epidemiological research and biomarker development are strengthening opportunities for earlier identification and disease monitoring. As treatment options and diagnostics evolve, stakeholders can use integrated market, pipeline, and epidemiological intelligence to understand changing opportunities across major geographies and plan future strategies.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Contact Person: Abhishek kumar
Email: info@delveinsight.com
